Quick Answer
ADMA BIOLOGICS, INC. reported R&D Expense of $4.76 million for fiscal year 2025.
ADMA BIOLOGICS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $4.76M | +162.7% |
| 2024 | $1.81M | -45.1% |
| 2023 | $3.30M | -8.7% |
| 2022 | $3.61M | -0.9% |
| 2021 | $3.65M | -38.3% |
| 2020 | $5.91M | +152.0% |
| 2019 | $2.34M | +134.4% |
| 2019 | $1.00M | -74.5% |
| 2018 | $3.93M | -29.5% |
| 2017 | $5.57M | -27.6% |
| 2016 | $7.69M | +9.6% |
| 2015 | $7.02M | -26.3% |
| 2014 | $9.52M | +2.3% |
| 2013 | $9.30M | +365.2% |
| 2012 | $2.00M | +209.2% |
| 2011 | $646.8K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.53M | +270.9% | +48.2% |
| June 30, 2025 | $1.03M | +84.1% | +24.8% |
| March 31, 2025 | $826.0K | +83.6% | +100.5% |
| September 30, 2024 | $412.0K | -30.9% | -26.4% |
| June 30, 2024 | $560.0K | -60.1% | +24.4% |
| March 31, 2024 | $450.0K | -47.4% | -24.5% |
| September 30, 2023 | $596.0K | -42.8% | -57.5% |
| June 30, 2023 | $1.40M | +60.6% | +64.1% |
- ADMA BIOLOGICS, INC. showed an increase of +162.7% in R&D Expense compared to the prior fiscal year.
- Over the 2011–2025 period, ADMA BIOLOGICS, INC.’s r&d expense has grown by 636.3% (from $646.8 thousand to $4.76 million).
- The most recent figure is from ADMA BIOLOGICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: